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Table of Contents summary: A retrospective study to evaluate the effect of hydroxyurea on 
nocturnal and daytime oxygen saturations in children with sickle cell disease. 
 
What’s Known on this Subject: Hypoxaemia and intermittent oxygen desaturation 
frequently occur in children with SCD and contribute to the associated morbidity. 
Hydroxyurea reduces the incidence of painful crises and acute chest syndrome by increasing 
fetal haemoglobin percentage in the blood.  
 
What this Study Adds: Children with sickle cell disease had higher overnight oxygen 
saturation on sleep studies and higher day-time spot oxygen saturation checks after starting 
hydroxyurea. Hydroxyurea is a potential treatment for persistent hypoxaemia in SCD pending 
further evidence from randomised controlled trials.
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ABSTRACT 
Introduction:  Sickle cell disease (SCD) is one of the most common inherited diseases 
worldwide. It is associated with lifelong morbidity and reduced life expectancy. Hydroxyurea 
(HU) has been shown to reduce the frequency and severity of vaso-occlusive episodes in 
SCD. Hypoxaemia and intermittent nocturnal oxygen desaturations occur frequently in 
children with SCD and contribute to the associated morbidity, including risk of 
cerebrovascular disease and vaso-occlusive episodes. 
Objective:  To evaluate the effect of HU on oxygen saturation (SpO2) overnight and on 
daytime SpO2 spot checks in children with SCD. 
Methods:  A retrospective review of children with SCD and respiratory problems who 
attended two UK tertiary sickle-respiratory clinics and were treated with HU. Longitudinal 
data was collected from 2 years prior and up to 3 years after the commencement of HU. 
Results:  
Forty three children, 23 males (53%) with a median age of 9 (range 1.8-18) years were 
included. In the 21 children who had comparable sleep studies before and after starting HU, 
mean SpO2 was higher (95.2% from 93.5%, p=0.01) and nadir SpO2 was higher (87% from 
84%, p=0.009) when taking HU. In 32 of the children, spot daytime oxygen saturations were 
also higher (96.3% from 93.5%, p=0.001).  
Conclusion: Children with SCD had higher oxygen saturation overnight and on daytime spot 
checks after starting HU. This data suggests HU may be helpful for treating persistent 
hypoxaemia in children with SCD pending more evidence from a randomised clinical trial. 
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INTRODUCTION   
Sickle cell disease (SCD) is one of the most prevalent inherited diseases, affecting 
approximately 300.000 newborns globally each year.[1] Hypoxaemia, a frequent 
complication of SCD, increases the risk of painful crises,[2] cognitive dysfunction,[3] central 
nervous system events,[4] and acute chest syndrome (ACS).[5] Children with SCD also have 
a high prevalence of obstructive sleep apnoea (OSA) which may contribute to nocturnal 
hypoxaemia.[6–9] Hydroxyurea (HU) increases production of fetal haemoglobin 
(HbF).[10,11] HbF percentage (HbF%) can rise from a mean of 5-10% to 15-20% during 
treatment with HU.[12] Increasing HbF% lowers the concentration of HbS within red cells 
resulting in less polymerisation and increased total haemoglobin. This results in fewer 
episodes of pain, hospitalisation and ACS.[13] The drug has a good safety profile in children 
with SCD.[11,14] Among possible side effects, mild gastrointestinal symptoms,[11] 
hyperpigmentation of the skin and darkening of the nails have been reported,[15] beyond the 
most common excessive myelosuppression, which is transient and reversible.[12] Chronic 
hypoxaemia is one the complications of SCD for which hydroxyurea therapy is now 
recommended in the UK.[16] However, evidence of a better oxygenation on HU has only 
been reported anecdotally by a case report,[17] a small study using spot pulse oximetry,[18] 
and a cross-sectional study comparing children with SCD and suspected OSA who were on 
HU with a larger group who were not.[19] To our knowledge, there have been no 
longitudinal studies looking at the effect of HU on oxygen saturations in SCD. As part of 
routine respiratory assessment in our centres, we have often conducted overnight 
oximetry/capnography in children with SCD who had respiratory complaints. Many who 
subsequently started HU therapy for various reasons had repeated sleep studies. We therefore 
had longitudinal data upon which to test the hypothesis that oxygenation would improve in 
children with SCD on HU.  
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METHODS  
Our study group were children followed at a tertiary respiratory clinics (King’s College 
Hospital) or joint respiratory-sickle cell clinics (Evelina London Children’s Hospital). As per 
standard practice, these children would have been assessed for respiratory co-morbidities 
(most commonly including wheezing and asthma, sleep disordered breathing -SDB-, chronic 
hypoxemia, recurrent acute chest syndrome, chronic cough and lung function abnormalities) 
and treated accordingly. We retrospectively collected longitudinal data on children with SCD 
who were seen in these clinics and who were commenced on HU between March 2006 and 
July 2014. We reviewed electronic and paper medical records for spot pulse-oximeter oxygen 
saturation (SpO2) readings recorded routinely in clinic. A Nonin GO2 pulse oximeter (Nonin, 
Plymouth, MN, USA) was used to measure SpO2, with the value recorded after at least two 
minutes of stable SpO2 readings and a clear pulsatile photoplethysmographic signal. Median 
values of these readings taken from 6 months prior to commencement of HU were compared 
to median values of readings taken up to 2 years after. Over the same time periods before and 
after starting HU, haemoglobin and fetal haemoglobin concentrations and spirometry data 
were also collected and averaged for comparison. Those who had oximetry/capnography 
sleep studies (TCM 4/40 monitoring system, Radiometer
®
, software version 3.0, SpO2 
averaging time 3 sec) done from 2 years before and up to 3 years after starting HU were 
identified for comparison of sleep study parameters within the same patient. Sleep studies 
were ordered in those patients who reported symptoms of SDB (e.g. loud snoring, witnessed 
apnoeas, restless sleep and mouth breathing) or had a previous history of OSA and were 
performed over a single night, during which parents or guardians kept a sleep diary. Artefacts 
due to poor perfusion, low signal identification and movement were manually excluded, as 
well as periods of wakefulness according to the sleep diary’s records. Studies with less than 4 
hours of artefact-free data were excluded. Analysis software provided standard measures 
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including overnight mean and nadir SpO2 and oxygen desaturation index (ODI), defined as 
the number of validated desaturations of at least 3% per hour of sleep. 
All the assessments were performed when the patients were at steady state, outside acute 
SCD-related acute events (e.g. vaso-occlusive crisis, acute chest syndrome etc).  
 
Statistical analysis  
Descriptive statistics are reported as medians with inter-quartile range. Group comparisons 
were performed using Wilcoxon matched-pairs signed-rank test, chi-squared test or Fisher’s 
exact test as appropriate. The relationship between night-time or daytime SpO2 and age at 
each data point was evaluated through Spearman’s rank correlation. A p-value <0.05 was 
considered as statistically significant. Statistical analysis was performed using Graphpad, 
version 6 for Windows (GraphPad Software, La Jolla California USA).  
 
 
RESULTS 
Forty three children, 23 (53%) male, were included. Three children were excluded due to lack 
of comparable data. Median age was 9 years (range 1.8-18). One child had 
HbS/β0thalassaemia, all the others had HbSS. There were no smokers among the adolescent 
patients enrolled. Six (14%) children had a history of recurrent ACS (figure 1) and two had 
severe hypoxaemia. Fifteen of them (35%) had asthma, which had been diagnosed at least 
one year before starting HU. Moreover, 17 children (40%) had previously undergone 
adenotonsillectomy for OSA, 3 of them after they started HU.  
Both at baseline and after starting HU, there were no statistically significant differences in 
median values of spot daytime SpO2 and overnight mean SpO2 between patients with or 
without asthma (data not shown). 
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The majority started HU due to frequent painful crises or very low steady-state haemoglobin. 
(Figure 1) The median dose of HU at 1-2 years after commencement was 22 mg/kg (IQR 20-
26, range 15-30),  
 
Overnight oxygenation 
Comparable sleep studies before and after starting HU were available on 21 children. 
Parameters from sleep studies done a median of 9 months (Interquartile range (IQR) 3.5 – 15 
months) before starting HU were compared to parameters from studies done a median of 9 
months (IQR 5-16months) after. Mean overnight oxygen saturations rose significantly from 
93.5 to 95.2% on HU (P=0.01), whilst nadir overnight oxygen saturations were also 
significantly higher (84 to 87%) on HU (P=0.009) (Table 1). There was no significant 
difference in the ODI. None of these parameters was related to age at each data point. When 
removing from the analysis three patients who underwent adenotonsillectomy after starting 
HU, increases of mean and nadir overnight SpO2 from baseline to endpoint were still 
significant (P< 0.05 for both outcomes; data not shown).  
Among 18 children with SDB and comparable ODI results from nocturnal oximetry before 
and after starting HU, the frequency of ODI ≥3, a cut-off highly predictive of OSA in 
children with SDB,[20] decreased from 8 (44%) pre-HU to 6 (33%) post-HU (P=0.7). Of 
these, 5 participants who had previously undergone adenotonsillectomy for OSA, had an ODI 
persistently ≥3, both before and while taking HU.  
Table 1. Changes in oxygen saturation parameters and haematological indices with 
hydroxyurea. 
 Patients with 
comparable 
data n.
 
Before HU 
Median (IQR) 
After HU 
Median (IQR) 
*p 
value 
Mean overnight SpO2 (%) 20 93 (88-97) 95 (93-98) 0.01 
Nadir overnight SpO2 (%) 20 84 (77-89) 87 (83-91) 
0.009 
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3% ODI overnight 
(events/hour) 
18 3.0 (1.5-5.2) 2.8 (1.1-4.6) 
0.08 
Spot daytime SpO2 (%) 32 93 (91-97) 96 (94-98) 
0.001 
Hb (g/L) 42 76.0 (69.5 – 86.5) 83.0 (72.7-87.7) 
0.04 
HbF (%) 37 6.1 (3.7-12.9) 8.8 (6.0-16.0) 
<0.001 
Neutrophil count (10
9
/L) 42 5.7 (4.3-6.8) 5.4 (3.9 – 6.2) 
0.1 
Definition of abbreviations: IQR = Interquartile Range; ODI = Oxygen desaturation index; HU = 
Hydroxyurea  
 
 
Averaged spot daytime oxygen saturation and other measures 
Comparable spot-checks of SpO2 in the daytime before and after starting HU was available in 
32 of the children. The median SpO2 rose by 2.8% (from 93.5% to 96.3%) after starting HU 
(Table 1). Before the intervention, SpO2 had a moderate negative correlation with age (rs = -
0.44, p = 0.01), but this relationship lost significance after HU was introduced (rs = -0.18. p = 
0.2). As expected Hb and HbF rose significantly on HU. There was a moderate positive 
correlation between changes in daytime SpO2 and changes in HbF level from baseline to 
endpoint (rs = 0.47, p = 0.02), as well as between changes in SpO2 and Hb concentration (rs = 
0.51, p = 0.007). No statistically significant changes in FEV1 and FVC % of predicted were 
found on HU but longitudinal lung function data was available on only 10 children (data not 
shown). 
Among SCD patients with asthma and with previous adenotonsillectomy, changes in daytime 
and nocturnal oxygen with HU therapy were similar to those of the whole sample but only 
variations of spot daytime SpO2 resulted significant (table S1), probably also for the limited 
number of observations in these subgroups.  
 
DISCUSSION 
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Our principal finding was that overnight mean SpO2 and nadir SpO2 were significantly higher 
after the commencement of HU in children with SCD. Averaged spot daytime oxygen 
saturations were also higher in the children when they were on HU.  
 
Hypoxaemia in SCD is reported to occur in 33-44% of patients[5,21] and is associated with 
increased risk of stroke,[22] pain crises,[2] increased tricuspid regurgitant jet velocity 
(TRJV)[23] and left ventricular abnormalities.[24] A low oxygen saturation in patients with 
SCD may depend on several causes, including elevated levels of carboxyhaemoglobin and 
methaemoglobin that are unable to carry oxygen,[25] asleep hypoxaemia due to disordered 
breathing,[7] and the rightward shift of the oxygen-haemoglobin dissociation curve (ODC) 
when HbS polymerizes.[26–28] In addition chronic anaemia, besides reducing oxygen 
carrying capacity, also leads to increased 2,3 DPG production and rightward shift of the 
ODC, resulting in a lower than expected oxyhaemoglobin saturation at a given PaO2.[29] 
 
There is limited evidence for the effect of HU on oxygenation in children with SCD. In 2008, 
Singh et al[17] published a report of 3 cases of children with SCD, recurrent episodes of ACS 
and chronic hypoxaemia. Spot daytime oxygen saturations were measured before and after 
the commencements of HU. Oxygenation improved soon after the commencement of HU and 
this effect was sustained up to the last follow up, 20-24 months later. 
Pashankar et al conducted a small prospective study[18] of 13 children with 
HbSS/Sβ0thalassemia who were prospectively treated with HU for 12 months for an elevated 
TRJV which has been associated with oxygen desaturation. HU significantly increased spot 
oxygen saturation and the improvement was sustained at 12 months post treatment. 
Compared to these reports, our study included a larger number of patients and integrated data 
from both nocturnal and daytime SpO2 from several data points for each patient, in order to 
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minimize possible bias due to variability in spot daytime SpO2 values at steady state.[26] 
Narang et al[19]
 
evaluated cross-sectionally overnight oxygen saturation in 37 children with 
SCD who were receiving HU compared with 104 who were not receiving HU. Patients 
enrolled were mainly referred with a history suggestive of OSA. Overnight sleep parameters 
for oxygenation (as well as awake spot oxygen saturations) were significantly higher in the 
HU group than in the non-HU group. However, the cross-sectional design of this study 
precludes the possibility of inferring whether its findings depended on the effect of HU or on 
different baseline characteristics of the study and control group. Moreover, the fact that most 
of the patients included suffered from SDB hinders the generalization of its conclusions to the 
entire SCD population. Our study confirmed the preliminary cross-sectional findings of 
Narang et al[19], showing that median asleep and waking SpO2 increased, respectively, by 
2% (p = 0.01) and 3% (p = 0.001), on a longitudinal evaluation covering up to 3 years from 
the introduction of HU. 
 
The precise mechanism by which HU increases HbF is not fully understood. Various theories 
have been postulated including a cytotoxic effect of HU on late erythroid precursors leading 
to recruitment of early erythroid precursors with increased capacity to produce HbF,[30] 
modification of transcription factors which alters the ratio of HbA to HbF[31] and a nitric-
oxide derived mechanism for HbF induction.[32] New theories continue to emerge, but all 
culminate in an increased production of HbF, which decreases the rate of HbS polymerisation 
thereby reducing the downstream pathological events, including haemolysis, anaemia, 
inflammation and tissue infarction. Besides, HbF has a higher affinity for oxygen than HbS or 
HbA due to its lower affinity for 2,3DPG, shifting the ODC to the left and increasing 
oxyhaemoglobin saturation for a given oxygen partial pressure in arterial blood. Interestingly, 
in the present study, though median increase of HbF after commencing HU was lower than 
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expected (table 1), we could still appreciate a significant increase of asleep and waking SpO2, 
moderately correlated with changes in Hb and HbF. 
 
Chronic hypoxaemia is an indication for children with SCD to be offered HU in the UK, 
although the recommendation is based on poor quality evidence (1C).[16] There is a need for 
evidence of clinical benefit that this study attempts to provide. Only two of the children in 
this study started HU due to hypoxaemia but a significant increase in oxygenation was still 
observed. We could only speculate whether a larger effect might have been seen if more of 
the children had had low baseline oxygen saturation. 
In our study, the majority of patients were started on HU because of frequent episodes of 
pain. They were on moderate doses of HU with some leeway for making increases. It is 
possible that larger improvements in oxygenation might have been achieved on higher doses. 
Reaching the maximum tolerated dose may be an appropriate strategy if hypoxaemia were 
the indication for HU.  
 
A strength of this study is that, at the best of our knowledge, it is the largest longitudinal 
evaluation of the effects of HU on oxygen saturation in patients with SCD. Furthermore, 
integrating both asleep and waking SpO2 data from multiple data points for each patient when 
they were asymptomatic, allowed to minimize possible biases due to intra-subject variability 
in SpO2 values, especially as regards to spot daytime SpO2.[33]  
A major limitation is the absence of a control group of patients with SCD who did not start 
HU treatment. This does not allow to exclude that changes in SpO2 over the study period 
were due to factors other than HU. For example changes in daytime and overnight oxygen 
saturation with HU in patients with asthma were similar to those of the general sample (table 
S1) but, since information on changes in severity of asthma symptoms and therapy over the 
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study period was not available, we cannot exclude that the improved oxygen saturation in this 
subgroup was due to an better asthma control from baseline to endpoint. Moreover, since in 
participants with SDB only data from nocturnal oximetry but not from polysomnography was 
available, the exact prevalence and trends of OSA over the study period could not be 
established. However, considering that the frequency of ODI≥3 in children with SDB did not 
change significantly from baseline to endpoint, it is unlikely that variations in the prevalence 
of OSA affected the results of nocturnal oximetry pre- and post-HU. Furthermore, when we 
performed the analysis excluding three patients who had adenotonsillectomy for OSA after 
starting HU (in these children improvements of SpO2 could depend on relief of upper airway 
obstruction rather than HU), differences in nocturnal SpO2 remained significant. Regarding 
other potential confounders, over the study period the centres involved did not apply major 
changes in the standards of care for SCD patients (apart from increasing use of HU), and the 
SpO2 would have been expected to decrease, rather than increase, by time.[5,21,34] 
Therefore, it is unlikely that variables not taken into account had a relevant influence on 
changes in oxygen saturation in patients on HU.  
Another limitation of this study is related to the use of pulse oximetry as measure of steady 
state oxygen saturation in children with SCD, as pulse oximetry tends to overestimate arterial 
oxygen saturation compared to co-oximetry (gold standard).[25,35] 
We were unable to measure adherence to HU therapy but the rise in HbF provided some 
induction that it was being taken. This relatively small study’s retrospective design meant 
data gaps were inevitable. There were not enough lung function data available to draw any 
conclusions here. Comparable sleep study data was available on only half the children who 
were receiving HU, and even then the reports were not easily available and some data had to 
be extracted from clinic letters. Selection bias could not be excluded as we only looked at 
children with SCD who were referred for respiratory symptoms. Indeed it was not possible to 
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control for confounding factors that may have affected SpO2 in addition to HU. To do so, a 
randomised placebo-controlled trial of HU therapy in children, would be required. Ethical 
approval for such a trial now may not be straightforward. Confining a study to a particular 
sub-group of children with SCD e.g. those with respiratory complaints in our case, or a 
particular indication for HU, helps to reduce confounding factors but then begs the question 
of whether conclusions can be generalised to other children with SCD. 
 
Conclusions 
Granting all the limitations of this study, the data does indicate higher oxygenation, both on 
overnight and daytime measurements, with HU therapy. This was despite the fact that less 
than 5% of the children with SCD had started HU because of persistent hypoxaemia. In other 
words, even children without resting hypoxaemia appear to have higher SpO2 on HU.  This 
study therefore provides important preliminary evidence upon which to justify giving HU to 
treat persistent hypoxaemia in children with SCD until better evidence from a randomised 
controlled clinical trial is forthcoming. 
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FIGURES 
Figure 1: Indications for starting hydroxyurea in 43 pediatric patients with sickle cell 
disease.  
*micro-albuminuria, retinopathy, recent severe pneumococcal sepsis 
 
